Immune system effects in children of mothers with multiple sclerosis treated during pregnancy
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how certain multiple sclerosis medicines (called monoclonal antibodies) given during pregnancy might affect the baby's immune system. It will help doctors understand if these treatments are safe for the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple sclerosis.
- You received a medicine like rituximab, ocrelizumab, or ofatumumab within 6 to 12 months before or during pregnancy.
- You received another immune-modulating treatment within 6 to 12 months before or during pregnancy.
- You did not receive any treatment within 6 to 12 months before or during pregnancy.
- You have not had a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the safety of ozanimod taken during pregnancy for parents with multiple sclerosis and for their babies after birth. It may help doctors understand the risks and benefits of this medicine during early pregnancy.
This study tracks pregnant women with certain chronic health conditions (like multiple sclerosis, lupus, or rheumatoid arthritis) and healthy pregnant women as a comparison group. It aims to understand how these conditions and their treatments affect pregnancy, the baby, and breast milk.
This study follows pregnant people with multiple sclerosis (MS) who took Mayzent (siponimod) to understand safety for pregnancy outcomes. It compares them with other groups to see whether there are any differences in birth results.
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
This study looks at the safety of Kesimpta (a multiple sclerosis medication) during pregnancy. It compares outcomes for women who took Kesimpta or other MS drugs while pregnant to those who did not.
This early study tests whether an IV infusion of donor-derived stem cells is safe for people with multiple sclerosis. It mainly focuses on side effects and safety, not whether it improves MS symptoms yet.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.